BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38238071)

  • 1. Small cell lung cancer with SYN2::PPARG fusion.
    Ghigna MR; Cotteret S; Arbab A; Bani MA; Scoazec JY
    Pathol Res Pract; 2023 Nov; 251():154904. PubMed ID: 38238071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
    Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
    Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of nasal low-grade non-intestinal-type adenocarcinoma with aberrant CDX2 expression and a novel SYN2-PPARG gene fusion in a 13-year-old girl.
    Soon GST; Chang KTE; Kuick CH; Petersson F
    Virchows Arch; 2019 May; 474(5):619-623. PubMed ID: 30666415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.
    Shi X; Duan H; Liu X; Zhou L; Liang Z
    Oncotarget; 2016 Jun; 7(23):34240-9. PubMed ID: 27145273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
    Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
    J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.
    Shiao TH; Chang YL; Yu CJ; Chang YC; Hsu YC; Chang SH; Shih JY; Yang PC
    J Thorac Oncol; 2011 Jan; 6(1):195-8. PubMed ID: 21178714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
    Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
    Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three metachronous primary lung cancers in a chronic smoker: A case report and review of the literature.
    Damania D; Chow L; Betancourt B; Mahoney J; Haseeb MA; Jabbar A; Gupta R; Sidhu G
    Medicine (Baltimore); 2020 Dec; 99(51):e22559. PubMed ID: 33371055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET mutation and expression in small-cell lung cancer.
    Dabir S; Babakoohi S; Kluge A; Morrow JJ; Kresak A; Yang M; MacPherson D; Wildey G; Dowlati A
    J Thorac Oncol; 2014 Sep; 9(9):1316-23. PubMed ID: 25122427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma: 
A Case Report and Literature Review].
    Qu Z; Liu J; Luo F; Li L; Zhu L; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):808-814. PubMed ID: 34802214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracheal polypoid combined small cell lung cancer (C-SCLC): A case report.
    Testori A; Ferraroli G; De Carlo C; Bossi P; Alloisio M; Mangiameli G
    Thorac Cancer; 2021 Jul; 12(13):2035-2038. PubMed ID: 33990130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
    Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
    Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
    Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
    Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
    Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
    Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.